WEE1 and leiomyosarcoma: Numerous other early‐stage trials are ongoing using another CDK4/6 inhibitor ribociclib, pairing it with the protein kinase inhibitor everolimus in DDLPS and leiomyosarcoma,40 and ribociclib and doxorubicin in metastatic/advanced STS.40, 41